Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Breast 1

Conditions

Breast Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma, Large B-Cell, Diffuse 28Multiple Myeloma 26Lymphoma 26Lymphoma, Non-Hodgkin 21Leukemia, Myeloid, Acute 21Leukemia, Lymphocytic, Chronic, B-Cell 21Neoplasms 20Myelodysplastic Syndromes 19Lymphoma, Follicular 18Recurrence 16Lymphoma, B-Cell 16Leukemia 16Burkitt Lymphoma 16Lymphoma, Mantle-Cell 15Triple Negative Breast Neoplasms 14Ovarian Neoplasms 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Neuroblastoma 10Lymphoma, B-Cell, Marginal Zone 10Hodgkin Disease 10Sarcoma 8Melanoma 8Medulloblastoma 8Rhabdomyosarcoma 7Myeloproliferative Disorders 7Leukemia, Biphenotypic, Acute 7Carcinoma, Non-Small-Cell Lung 6Brain Neoplasms 6

Interventions

Magnetic Resonance Spectroscopy 9pembrolizumab 7Specimen Handling 7Biopsy 7Leucovorin 5Gemcitabine 5Cisplatin 5durvalumab 4Oxaliplatin 4Fluorouracil 4Capecitabine 4Paclitaxel 3Nivolumab 3Irinotecan 3Carboplatin 3tislelizumab 2olaparib 2fludarabine 2atezolizumab 2Trastuzumab 2Taxes 2Radiation Dose Hypofractionation 2Radiation 2Ipilimumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zimberelimab 1varlilumab 1tucatinib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Cholangiocarcinoma × Cyclophosphamide × Clear all
NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡